---
title: Viking Therapeutics (VKTX) — stock overview: intrinsic value, grades and financials
canonical: https://sweetvaluelab.com/stocks/vktx
ticker: VKTX
as_of: 2026-11-02
sector: Healthcare
industry: Biotechnology
---
# Viking Therapeutics (VKTX)

Viking Therapeutics (VKTX) holds a Quant grade of D (model v1, Oct 30), on a scale from S, the best, to D. It closed at $27.28 on Oct 30, 2026. The models produced no usable value for it on this snapshot.

Among the superinvestors tracked here, Bridgewater added. The latest filing is a 10-Q (quarterly report), filed Oct 29.

The valuation in full, model by model: https://sweetvaluelab.com/stocks/vktx/valuation.

## Key figures

| Figure | Value |
| --- | ---: |
| Last close | $27.28 (Oct 30, 2026) |
| Model value (median of the weighted models) | none — out of range |
| Price vs model | — |
| Range across the models | $0.00 – $0.00 |
| Market value | $3.5B |
| P/E (fiscal 2025) | — |
| Net margin (fiscal 2025) | 0.0% |
| Free cash flow (fiscal 2025) | -$278.7M |
| Dividend yield (trailing twelve months) | 0.00% |
| Beta | 0.65 |
| Cost of capital (WACC) | 8.10% |
| Business classification | Loss-Making (Revenue declining (~0% recent), Currently unprofitable) |

## The last eight quarters

| Quarter | Revenue | Change on a year earlier | Operating margin |
| --- | ---: | ---: | ---: |
| Q4 FY2024 | $0 | — | — |
| Q1 FY2025 | $0 | — | — |
| Q2 FY2025 | $0 | — | — |
| Q3 FY2025 | $0 | — | — |
| Q4 FY2025 | $0 | — | — |
| Q1 FY2026 | $0 | — | — |
| Q2 FY2026 | $0 | — | — |
| Q3 FY2026 | $0 | — | — |

Twelve months to Q3 FY2026, against the twelve before:

| Line | Latest | Year before |
| --- | ---: | ---: |
| Revenue | $0 | $0 |
| Operating income | -$648.6M | -$274.8M |
| Net income | -$627.2M | -$237.4M |
| Free cash flow | -$462.6M | -$224.6M |
| Diluted EPS | -$5.41 | -$2.12 |

## Valuation models

Each model's value per share and the role the engine gave it for this business. The headline above is the median of the primary and cross-check models; sanity checks are shown, not weighted. Computed Nov 2, 2026.

| Model | Role | Value per share | Low | High |
| --- | --- | ---: | ---: | ---: |
| DCF · Perpetuity growth · 5y | primary | $0.00 | $0.00 | $0.00 |
| DCF · Perpetuity growth · 10y | cross check | $0.00 | $0.00 | $0.00 |
| DCF · EBITDA exit · 5y | cross check | $0.00 | $0.00 | $0.00 |
| DCF · EBITDA exit · 10y | cross check | $0.00 | $0.00 | $0.00 |
| EV/EBITDA · peers | cross check | $0.00 | $0.00 | $0.00 |
| EV/Revenue · peers | cross check | $0.00 | $0.00 | $0.00 |
| Earnings power value | cross check | $0.00 | $0.00 | $0.00 |
| Dividend discount | cross check | $0.00 | $0.00 | $0.00 |

## Wall Street analysts

The median of each covering firm's latest price target is $85.00, from 3 firms — the analysts' figure, quoted, and not part of the model value above. Each firm's latest target, the current grades, the grade changes and the consensus revenue and EPS estimates: https://sweetvaluelab.com/stocks/vktx/analysts (Markdown: https://sweetvaluelab.com/stocks/vktx/analysts.md).

## Insider activity (SEC Form 4)

No open-market insider buys or sales filed in the past 90 days.

| Date | Insider | Relationship | Transaction | Shares | Value |
| --- | --- | --- | --- | ---: | ---: |
| Aug 1, 2026 | Kelly-Gemmell Dorothy Elizabeth | Director | Grant / award | 6,333 | $0 |
| Aug 1, 2026 | Kelly-Gemmell Dorothy Elizabeth | Director | Grant / award | 40,800 | $0 |
| Jul 28, 2026 | Lian Brian | President & CEO | Grant / award | 221,667 | $0 |
| Jul 29, 2026 | Lian Brian | President & CEO | Open-market sell | 148,517 | $4.9M |
| Jul 28, 2026 | ZANTE GREG | Chief Financial Officer | Grant / award | 31,667 | $0 |

## Recent SEC filings

| Filed | Form | What | Filing |
| --- | --- | --- | --- |
| Oct 29, 2026 | 10-Q | Quarterly report | https://www.sec.gov/Archives/edgar/data/1607678/000119312526436432/vktx-20260930.htm |
| Oct 28, 2026 | 8-K | 2.02 Results of Operations (Earnings); 9.01 Financial Statements and Exhibits | https://www.sec.gov/Archives/edgar/data/1607678/000119312526436145/vktx-20261028.htm |
| Sep 28, 2026 | 8-K | 1.01 Entry into a Material Agreement; 2.03 Creation of a Direct Financial Obligation; 9.01 Financial Statements and Exhibits | https://www.sec.gov/Archives/edgar/data/1607678/000119312526405580/vktx-20260923.htm |
| Sep 25, 2026 | 424B5 | Prospectus supplement | https://www.sec.gov/Archives/edgar/data/1607678/000119312526401385/vktx-20260925.htm |
| Sep 25, 2026 | 424B5 | Prospectus supplement | https://www.sec.gov/Archives/edgar/data/1607678/000119312526401384/vktx-20260925.htm |

## Superinvestors holding it (latest 13F)

| Manager | Quarter | Shares | Value |
| --- | --- | ---: | ---: |
| Bridgewater | 2026-06-30 | 87,859 | $3.4M |

1 tracked managers in all.

## About

Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRß). This compound is currently progressing through Phase IIb clinical trials, targeting both non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients and non-alcoholic fatty liver disease (NAFLD). Viking's pipeline also features VK5211, an oral, non-steroidal selective androgen receptor modulator undergoing Phase II studies for individuals recuperating from non-elective hip fracture surgery. Additionally, VK0612, an oral drug candidate for type 2 diabetes, is poised to enter Phase IIb trials. The firm is also developing VK0214, another orally active, tissue…

---

Source: https://sweetvaluelab.com/stocks/vktx (SweetValueLab, free, no account). Prices and statements from Financial Modeling Prep; filings from SEC EDGAR. Research and educational data, not investment advice; nothing here is a recommendation to buy, sell or hold any security.